PeptideScanner retained ClinicalTrials.gov record NCT03395574 at 2026-11-15T21:47:40.408Z. Its registry update date was 2018-12-24, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT01153581 at 2026-11-15T22:03:26.540Z. Its registry update date was 2018-12-13, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT01073865 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT03771326 at 2026-11-15T22:12:06.897Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was kisspeptin-10.
PeptideScanner retained ClinicalTrials.gov record NCT00073580 at 2026-11-15T21:58:19.888Z. Its registry update date was 2018-11-30, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00690235 at 2026-07-30T21:07:45.452Z. Its registry update date was 2018-11-16, and PeptideScanner's reviewed identity mapping was pramlintide.
PeptideScanner retained ClinicalTrials.gov record NCT02153723 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-11-05, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01469572 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-10-18, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00886262 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01932970 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT02127970 at 2026-11-16T17:37:42.807Z. Its registry update date was 2018-09-28, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT02473809 at 2026-07-30T21:10:03.006Z. Its registry update date was 2018-09-26, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00455689 at 2026-07-30T21:10:02.989Z. Its registry update date was 2018-09-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00711802 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01419184 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01112358 at 2026-11-15T22:02:39.332Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01728376 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01922011 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT03634137 at 2026-07-30T21:10:03.005Z. Its registry update date was 2018-08-16, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT00283803 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT00223665 at 2026-07-30T21:10:02.996Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03619330 at 2026-07-30T21:10:02.994Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02078323 at 2026-07-30T21:10:02.997Z. Its registry update date was 2018-07-23, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT02506023 at 2026-11-16T01:33:21.554Z. Its registry update date was 2018-07-16, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT02104739 at 2026-07-30T21:10:03.007Z. Its registry update date was 2018-07-03, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00926380 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-29, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02717858 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-28, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02064348 at 2026-07-30T21:11:31.040Z. Its registry update date was 2018-06-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01012089 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-06-06, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01718613 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-05-18, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00845507 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-04-20, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01137682 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-04-05, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01777542 at 2026-11-16T17:35:13.282Z. Its registry update date was 2018-03-26, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT01544998 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-03-22, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00966355 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-03-19, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01496131 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-03-09, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT02527993 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-03-07, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01046721 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-03-06, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01680653 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-03-05, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00730171 at 2026-07-30T21:12:47.419Z. Its registry update date was 2018-02-19, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT01393704 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT02217800 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01977859 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01103440 at 2026-11-15T21:59:29.646Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT02092597 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-02-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00882557 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT02660346 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-01, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00845182 at 2026-07-30T21:12:47.410Z. Its registry update date was 2018-01-18, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01191840 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-05, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02608996 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-01-03, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide.